MACRO (Multidisciplinary Acute Care Research Organization)

Newsletter Editor
Meghan Buck

Executive Committee:
Clifton Callaway, MD, PhD
Barb Early, BSN, CCRC
Scott Gunn, MD
David Huang, MD, MPH
Jason Sperry, MD, MPH
Mazen Zenati, MD, MPH, PhD

In this Issue
EUPHRATES 1
Early - Publication 1
ProCESS 2
GRAIL 2
Current Studies 3

Beginning in March 2013, MACRO began screening and enrolling for EUPHRATES (Evaluating the Use of Polymyxin (PMX) B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock). Dr. Ivonne Daly is the UPMC Principal Investigator and MACRO's lead coordinator is Marcy Lindley. Co-Investigators are Raghavan Murugan, Murat Kaynar, Jose Bernardo, Kelly Liang, and David Huang.

EUPHRATES is a double-blinded, randomized, controlled trial. The primary objective is to compare the safety and efficacy of the PMX cartridge based on mortality at 28-days in subjects with septic shock who have high levels of endotoxin and are treated with standard medical care plus use of the PMX cartridge, versus subjects who receive standard medical care alone.

As of July 31, 2013, MACRO has enrolled nine patients in EUPHRATES. MACRO’s screening and enrollment efforts with GRAIL (next page) are synergistic with EUPHRATES, as both studies target somewhat similar patient populations, and also share Co-investigators.

Nationwide, The University of Pittsburgh / MACRO’s enrollment rank is currently second.

Thank you to all the clinical staff that assists with research. Your cooperation is vital to our mission of improving care for critically ill patients through scientific study. We are always available. Please call with any questions or potential candidates for a research study.

Above, First row: Dr. Ivonne Daly (PI), Second row: CRC's, Marcy Lindley, Pam Fazio, Mary Kruth, Back row: CTRA, Ryan Begun, CRC, Denise Scholl, and Dialysis RN, Pat Seddon.

MACRO Clinical Coordinator Director, Barbara Early, recently first authored a publication in the Journal of Trauma and Acute Care Surgery based on her oral presentation at the 26th EAST Annual Scientific Assembly.

Multidisciplinary acute care research organization (MACRO): If you build it, they will come

ProCESS is a National Institutes of Health-funded multicenter interventional study to assess alternative resuscitation strategies for early septic shock.

On May 31, 2013 the ProCESS study hit its enrollment goal of 1350 to close the study. The University of Pittsburgh / MACRO ranked sixth out of 31 hospitals throughout the United States, for total enrollment.

MACRO Director, David Huang, serves as Medical Monitor for ProCESS, and MACRO Steering Committee members Donald Yealy and Derek Angus are Principal Investigators for ProCESS.

---

**THE GRAIL STUDY**

A Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure

- Dr. Scott Gunn recently resumed the Principal Investigator role for the GRAIL Study. Dr. Gunn is an Associate Professor of Critical Care Medicine and Emergency Medicine.

- The University of Pittsburgh / MACRO has moved in to second place nationwide for enrollment! Total subjects enrolled to date is twelve, and for 2013, eight.

- Thank you MACRO CRC’s for all of your screening and enrolling efforts 😊
### Actively Recruiting Studies

**Presby/Montefiore ICUs**

- **CMV** – A study to determine whether CMV reactivation impact outcomes in critically ill patients with sepsis due to blood stream infections.  
  PI – Nina Singh

- **ELAD** – Extracorporeal liver assist device for alcohol induced liver decompensation.  
  PI – Ali Al-Khafaji

- **Euphrates**—Endotoxin filtration using dialysis circuit for septic patients.  
  PI – Ivonne Daly

- **GRAIL** – A study for prevention of cytomegalovirus (CMV) in patients who have an established respiratory failure, including ALI, associated with either severe sepsis or trauma  
  PI – Scott Gunn

- **RECAP** – Impact of blood storage duration on physiologic measures  
  PI – Hernando Gomez

- **RUBY** – A study to collect blood and urine samples to help identify and validate protein biomarkers of recovery from moderate or severe acute kidney injury (AKI).  
  PI – Ali Al-Khafaji

**Presby Emergency Department**

- **AMPAr** – This study examines biomarkers and neurologic “IMPACT” testing in trauma patients with mild traumatic brain injury.  
  PI – David Okonkwo

- **POINT** – The study goal is to determine the safety and effectiveness of the combination of low-dose aspirin and clopidogrel (Plavix®) in reducing the risk of stroke, heart attacks and other complications in patients who have just had a TIA or minor ischemic stroke.  
  PI – Vivek Reddy

- **SHINE** – A two-arm, multicenter, randomized, prospective clinical trial designed to test the safety and efficacy of tight glucose management (glu 80-130mg/dL) via continuous infusion of insulin versus control therapy (glu <180mg/dL) via subcutaneous insulin injections in patients that present with hyperglycemia after an acute ischemic stroke.  
  PI – Lori Shutter

- **STONE** – The primary objective of this randomized multi-center study is to determine the effect of tamsulosin on the proportion of patients passing a kidney stone as determined by patient report.  
  PI – Allan Wolfson

- **TRAC** – This is a research study to help us find out whether people 18-25 years old will make safer decisions as a result of exposure to a mobile-phone text-message-based dialog that takes place over a 12-week period.  
  PI – Brian Suffoletto

**MERCY Emergency Department**

- **AMPAr** – This study examines biomarkers and neurologic “IMPACT” testing in trauma patients with mild traumatic brain injury.  
  PI – David Okonkwo

- **SHINE** – A two-arm, multicenter, randomized, prospective clinical trial designed to test the safety and efficacy of tight glucose management (glu 80-130mg/dL) via continuous infusion of insulin versus control therapy (glu <180mg/dL) via subcutaneous insulin injections in patients that present with hyperglycemia after an acute ischemic stroke.  
  PI – Lori Shutter

- **TRAC** – This is a research study to help us find out whether people 18-25 years old will make safer decisions as a result of exposure to a mobile-phone text-message-based dialog that takes place over a 12-week period.  
  PI – Brian Suffoletto